Articles from Apnimed, Inc.

CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed”), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced the closing of its upsized initial public offering of an aggregate of 13,800,000 shares of its common stock, including the full exercise by the underwriters of their overallotment option to purchase 1,800,000 additional shares, at an initial public offering price of $16.00 per share. All of the shares of common stock were offered by Apnimed. Apnimed’s common stock began trading on the Nasdaq Global Select Market on July 31, 2026, under the ticker symbol “APMD”.

CAMBRIDGE, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on discovery, development and commercialization of novel oral therapies for the treatment of obstructive sleep apnea (OSA) and other sleep disorders, announced a series of five data presentations and a dinner symposium at the SLEEP 2024 annual meeting. Presentations include an epidemiologic study of the prevalence of obesity in OSA, which demonstrates that the majority of people with OSA are not obese. OSA is estimated to affect more than 50 million in the United States, though underdiagnosis continues to be a serious problem.

- Apnimed to Present Rationale and Design of LunAIRo Phase 3 Study for AD109 at the ATS 2024 International Conference

CAMBRIDGE, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- The Boston Business Journal has named Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, including its lead oral treatment candidate AD109, to its 2024 Best Places to Work — the BBJ’s exclusive ranking of the Massachusetts companies that have built outstanding work environments for their people.

CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, including its lead oral treatment candidate AD109, today announced the company will participate in the 23rd Annual Needham Virtual Healthcare Conference taking place virtually on April 8-11, 2024.

CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, including its lead oral treatment candidate AD109, today announced the company will participate in the Leerink Partners Global Biopharma Conference taking place in Miami on March 11-13, 2024.

CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, including its lead oral treatment candidate AD109, today announced the company will participate in the Evercore ISI 2024 Emerging Biotech Conference taking place virtually on February 28-29, 2024.

CAMBRIDGE, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, today announced Graham Goodrich has joined the company as Chief Commercial Officer and Ted Harding as Chief Human Resources Officer. The addition of Goodrich and Harding are critical new hires as Apnimed prepares to launch AD109 (aroxybutynin/atomoxetine), a potential nighttime oral treatment currently in Phase 3 that could transform the treatment paradigm for millions of OSA patients.

-- SynAIRgy Compares AD109 to Placebo Over 6 Months in People with OSA who Are Intolerant of or Refuse Positive Airway Pressure (PAP) Therapy, the Current Standard of Care

CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, including its lead oral treatment candidate AD109, announced today the company will participate in the following investor conferences in November 2023:

$150M transaction supporting early and clinical-stage pipeline development in OSA and related sleep disorders to find oral pharmacologic solutions for people who cannot use or tolerate current therapies

CAMBRIDGE, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, announced that recent data on AD109 (aroxybutynin/atomoxetine) will be featured in an oral presentation at World Sleep 2023 symposium in Rio de Janeiro, Brazil. AD109 is a potential first-in-class, novel pharmacologic that is specifically designed to target the key neurological pathways in OSA that activate upper airway dilator muscles to maintain an open airway during sleep. It is currently in Phase 3 clinical trials.

CAMBRIDGE, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, including its lead oral treatment candidate AD109, announced today the company will be participating in the following investor conferences in October 2023:

-- Phase 3 Clinical Trials for AD109 Currently Enrolling Patients in the U.S.

CAMBRIDGE, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, today announced the appointment of Paul Fonteyne, MS, MBA, to its Board of Directors as an Independent Director. Fonteyne brings decades of experience in corporate leadership in biopharmaceuticals as well as a track record of commercial success, including as the former President, CEO and Chairman of Boehringer-Ingelheim USA. Fonteyne replaces Ruoxi (Rosy) Hu, PhD, from Morningside Technology Advisory, LLC, who stepped down from the Board.

-- LunAIRo Compares AD109 to Placebo Over 6 and 12 Months in People with OSA who Are Intolerant of or Refuse Positive Airway Pressure (PAP) Therapy, the Current Standard of Care --

- Seasoned biopharma medical leader joins Apnimed as it initiates its Phase 3 clinical program for AD109, a potential new oral treatment for Obstructive Sleep Apnea

-- New Post-Hoc Analysis of MARIPOSA Data on Estimating OSA Endotypes from theOxyhemoglobin Saturation Signal in Patients Dosed with AD109 for 1 Month

CAMBRIDGE, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, including its lead oral treatment candidate AD109, announced today the company will be participating in several investor conferences in September 2023. Please see additional details below:

CAMBRIDGE, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, including its lead oral treatment candidate AD109, announced today that Fierce Biotech named it as one of 2023’s “Fierce 15” biotechnology companies. The selection is a recognition given to the industry’s most innovative and promising biotechnology companies who are pushing the boundaries in the clinic and beyond.

CAMBRIDGE, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, including its lead oral treatment candidate AD109, announced today the company will be participating in the upcoming 43rd Annual Canaccord Genuity Global Growth Conference at the InterContinental in Boston, Massachusetts on Wednesday, August 9, 2023. Investors are invited to view the live session and participate in one-on-one meetings. Please see additional details below:

CAMBRIDGE, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, announced today that it will be participating in a fireside chat at the William Blair Conference, Transitioning Biotech Breakthroughs to Commercial Success, taking place virtually on Tuesday, July 18, 2023 at 8 a.m. ET.

CAMBRIDGE, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, announced that it will be participating in the 2023 BIO International Convention being held June 5-8 at the Boston Convention & Exhibit Center, Boston, MA.

-- New MARIPOSA Study Data Showed AD109 Statistically Significantly Improved Both Objective and Subjective Outcomes in OSA Patients

Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, announced that data from the MARIPOSA Phase 2b trial, an efficacy, safety and dose-finding study of one-month duration, will be featured in both an oral presentation and a poster presentation at The American Thoracic Society’s ATS 2023 International Conference in Washington, DC.

Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, including its lead oral treatment candidate AD109, today announced that Company management will present and host one-on-one investor meetings at the 22nd Needham Healthcare Conference taking place virtually April 17-20, 2023.

Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, including its lead oral treatment candidate AD109, today announced that company management will participate in 1x1 investor meetings at the SVB Securities Global Biopharma Conference taking place virtually January 31- February 2, 2023. The Apnimed meeting schedule will be accessible to registered conference attendees.

Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, announced today that it has secured $79.75 million in an oversubscribed financing round that extends its Series C financing to a total of $142.25 million. The financing was led by existing investor Alpha Wave Ventures and included existing investors Sectoral Asset Management, Columbia-Seligman Investments and Tao Capital Partners, among others.